Isolated hepatic perfusion for unresectable hepatic malignancies: A systematic review and meta-analysis

Table 3 Isolated hepatic perfusion details and response rate

Ref.	Patients evaluable for response (n)	IHP/PIHP	IHP chemotherapy protocol					Patient response				Overall response (CR + PR, %)
			Drug	Dose	Perfusion temperature	Perfusion time	Courses per patient (n)	Complete response (%)	Partial response (%)	Stable disease (%)	Progressive disease (%)
Olofsson et al[55]	34	IHP	Melphalan	1 mg/kg	40 °C	60 min	1	4 (12%)	19 (56%)	6 (18%)	5 (15%)	68%
Magge et al[56]	68	IHP	Melphalan Oxaliplatin Oxaliplatin + 5FU	1.5 mg/kg 40 mg/m2 5FU 200 mg/m2	40 °C	60 min	1	44 (64.7%)		24 (35.3%)		64.7%
Fukumoto et al[57]	67	PIHP	Mitomycin C and/or Doxorubicin	20-40 mg/m2 60-120 mg/m2	NR	30-40 min	1.51 (range 1-3)	21 (31.3%)	27 (40.3%)	11 (16.4%)	8 (11.9%)	71.6%
Alexander et al[58]	114	IHP	Melphalan TNF alone or both	1.5 mg/kg 1 mg	39.5 °C-40 °C	60 min	1	2 (1.8%)	67 (58.8%)	NR	NR	60.5%
van Iersel et al[59]	97	IHP	Melphalan	200 mg	39.5 °C	60 min	1	3 (3.1%)	49 (50.5%)	23 (23.7%)	22 (22.7%)	53.6%
Rizell et al[60]	27	IHP	Melphalan With or without TNF	0.5, 1 and 2 mg/kg 30 μg	≥ 40 °C	40-60 min	1	2 (7.4%)	17 (63.0%)	2 (7.4%)	6 (22.2%)	69.4%
Pingpank et al[61]	27	PIHP	Melphalan	2-3.5 mg/kg	NR	60 min	2.64	2 (7.4%)	6 (22.2%)	NR	NR	29.6%
Alexander et al[62]	29	IHP	Melphalan	1.5 mg/kg	NR	60 min	1	3 (10%)	15 (52%)	NR	NR	62%

NR: Not reported. IHP: Isolated hepatic perfusion; PIHP: Percutaneous isolated hepatic perfusion.